Monte Rosa Therapeutics (GLUE) Treasury Shares (2020 - 2026)

Monte Rosa Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Treasury Shares fell 98.13% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 98.13% decrease from a year earlier, with the FY2025 full-year figure at $65.5 million, up 6.56% from the prior year.
• Treasury Shares climbed to $1.1 million in Q1 2026 per GLUE's latest filing, from $775765.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $61.8 million in Q3 2025 and bottomed at $775765.0 in Q4 2025.
• The 5-year median for Treasury Shares is $50.1 million (2023), against an average of $47.7 million.
• Across the five-year window, Treasury Shares soared 16191.03% in 2022 and plunged 98.74% in 2025, its largest moves.
• Year by year, Treasury Shares stood at $49.3 million in 2022, then grew by 1.66% to $50.1 million in 2023, then grew by 22.67% to $61.5 million in 2024, then plunged by 98.74% to $775765.0 in 2025, then soared by 48.11% to $1.1 million in 2026.
• Per Business Quant, the three latest GLUE Treasury Shares figures stand at $1.1 million (Q1 2026), $775765.0 (Q4 2025), and $61.8 million (Q3 2025).